logo-loader
viewArc Minerals Limited

Arc Minerals hits more elevated copper grades at Kalaba

Newsflow is set to accelerate as the drill programme continues

1539673646_copper-periodic-table.jpg
Arc's drilling programme is leading to a greater understanding of the geology at Kalaba

Arc Minerals LTD (LON:ARCM) has intersected mineralisation in all holes drilled to date as part of the current 11,000-metre programme at the Kalaba prospect in Zambia.

Kalaba is part of the Zamsort copper-cobalt project which Arc took control of earlier in the year.

WATCH: Arc Minerals confident it could be sitting on 'something quite significant' at Zamsort

The four most recent holes have intersected elevated copper grades ranging from 0.50% to 1%, including 128 metres at 0.74% copper equivalent from the surface.

The company also hit 75 metres at 0.85% copper equivalent from the surface, and 59.5 metres at 0.87% copper equivalent from a depth of 2.8 metres.

"The results of our drilling programme continue to be very encouraging with these further drill results showing elevated copper intersections,” said Arc’s executive chairman Nick von Schirnding.

“The drilling to date demonstrates that at Kalaba the source and migration of the mineralising fluids have been quite extensive and we are now beginning to intersect some of the higher grade 'traps'. Given the activity on the ground as well as a large number of samples that are currently being sent to the lab, we anticipate a strong pipeline of news flow and we look forward to updating shareholders on these developments."

 

 

Quick facts: Arc Minerals Limited

Price: 2.8 GBX

AIM:ARCM
Market: AIM
Market Cap: £20.66 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics' Glyn Edwards talks US$50mln backing and ridinilazole...

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) CEO Glyn Edwards sat down with Proactive London's Andrew Scott following the news of a US$50mln funding deal with biotech billionaire Bob Duggan. The investment will help get the company’s next-generation antibiotic through phase III clinical...

5 hours, 49 minutes ago

2 min read